GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eton Pharmaceuticals Inc (NAS:ETON) » Definitions » ROC (Joel Greenblatt) %

Eton Pharmaceuticals (Eton Pharmaceuticals) ROC (Joel Greenblatt) % : -7,523.23% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Eton Pharmaceuticals ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Eton Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7,523.23%.

The historical rank and industry rank for Eton Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:

ETON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2314.13   Med: -904.63   Max: -41.07
Current: -610.03

During the past 7 years, Eton Pharmaceuticals's highest ROC (Joel Greenblatt) % was -41.07%. The lowest was -2314.13%. And the median was -904.63%.

ETON's ROC (Joel Greenblatt) % is ranked worse than
93.33% of 1065 companies
in the Drug Manufacturers industry
Industry Median: 7.85 vs ETON: -610.03

Eton Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 35.50% per year.


Eton Pharmaceuticals ROC (Joel Greenblatt) % Historical Data

The historical data trend for Eton Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eton Pharmaceuticals ROC (Joel Greenblatt) % Chart

Eton Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -1,227.79 -1,663.25 -41.07 -252.72 -581.46

Eton Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,265.60 -4,179.79 8,920.00 -1,281.87 -7,523.23

Competitive Comparison of Eton Pharmaceuticals's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Eton Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eton Pharmaceuticals's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eton Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Eton Pharmaceuticals's ROC (Joel Greenblatt) % falls into.



Eton Pharmaceuticals ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.495 + 1.051 + 0.541) - (8.853 + 0 + 0)
=-3.766

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.411 + 0.911 + 1.129) - (10.861 + 0 + 0)
=-5.41

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Eton Pharmaceuticals for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-11.172/( ( (0.147 + max(-3.766, 0)) + (0.15 + max(-5.41, 0)) )/ 2 )
=-11.172/( ( 0.147 + 0.15 )/ 2 )
=-11.172/0.1485
=-7,523.23 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eton Pharmaceuticals  (NAS:ETON) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Eton Pharmaceuticals ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Eton Pharmaceuticals's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eton Pharmaceuticals (Eton Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
21925 West Field Parkway, Suite 235, Deer Park, IL, USA, 60010-7278
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.
Executives
David Krempa officer: Chief Business Officer 29125 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Sean Brynjelsen director, officer: President & CEO C/O ETON PHARMACEUTICALS, INC., 21925 W FIELD PKWY #235, DEER PARK IL 60010
James R. Gruber officer: Chief Financial Officer 618 AMES STREET, LIBERTYVILLE IL 60048
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
William Wilson Troutman officer: CFO, Treasurer & Secretary 21925 W FIELD PARKWAY, SUITE 235, DEER PARK IL 60010
Imprimis Pharmaceuticals, Inc. 10 percent owner 102 WOODMONT BLVD, SUITE 610, NASHVILLE TN 37215
Jennifer Mckie Adams director 5410 TENNESSEE AVE, NASHVILLE TN 37209
Charles J Casamento director 99 BELBROOK WAY, ATHERTON CA 94027
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Mark L Baum director C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121

Eton Pharmaceuticals (Eton Pharmaceuticals) Headlines

From GuruFocus

Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer

By GuruFocusNews GuruFocusNews 04-11-2022

Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference

By Value_Insider Value_Insider 10-18-2022